AU Patent

AU2024208501A1 — Ligand-drug conjugates

Assigned to Sun Pharma Advanced Research Co Ltd · Expires 2025-07-24 · 1y expired

What this patent protects

The present invention generally relates to Ligand-drug conjugates of the Formula I: or pharmaceutically acceptable salts, stereoisomers or isotopes thereof. The invention further relates to the use of the compound of Formula I, for the treatment of cancer.

USPTO Abstract

The present invention generally relates to Ligand-drug conjugates of the Formula I: or pharmaceutically acceptable salts, stereoisomers or isotopes thereof. The invention further relates to the use of the compound of Formula I, for the treatment of cancer.

Drugs covered by this patent

lutetium-lu-177-vipivotide-tetraxetan (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN)

Patent Metadata

Patent number: AU2024208501A1
Jurisdiction: AU
Classification: —
Expires: 2025-07-24
Drug substance claim: No
Drug product claim: No
Assignee: Sun Pharma Advanced Research Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.